山东大学学报 (医学版) ›› 2022, Vol. 60 ›› Issue (9): 125-128.doi: 10.6040/j.issn.1671-7554.0.2022.0080
孙文雄1,吴日超2,郑贤静3,李丽4, 张友忠1
中图分类号:
| [1] Hornick JL, Fletcher CD. PEComa: what do we know so far?[J]. Histopathology, 2006, 48(1): 75-82. [2] Kallen ME, Hornick JL. The 2020 WHO classification: whats new in soft tissue tumor pathology?[J]. Am J Surg Pathol, 2021, 45(1): e1-e23. [3] Fadare O. Perivascular epithelioid cell tumor(PEComa)of the uterus: an outcome-based clinicopathologic analysis of 41 reported cases[J]. Adv Anat Pathol, 2008, 15(2): 63-75. [4] Kenerson H, Folpe AL, Takayama TK, et al. Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms[J]. Hum Pathol, 2007, 38(9): 1361-1371. [5] Kovac O, Babal P, Kajo K, et al. Perivascular epithelioid cell tumor(PEComa)of the uterine cervix: a case report of a 43-yr-old woman with abnormal utering treated with hysterectomy[J]. Int J Gynecol Pathol, 2018, 37(5): 492-496. [6] Bennett JA, Braga AC, Pinto A, et al. Uterine PEComas: a morphologic, immunohistochemical, and molecular analysis of 32 tumors[J]. Am J Surg Pathol, 2018, 42(10): 1370-1383. [7] Folpe AL, Mentzel T, Lehr HA, et al. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature[J]. Am J Surg Pathol, 2005, 29(12): 1558-1575. [8] Bennett JA, Ordulu Z, Pinto A, et al. Uterine PEComas: correlation between melanocytic marker expression and TSC alterations/TFE3 fusions[J]. Mod Pathol, 2022, 35(4): 515-523. [9] Rao Q, Cheng L, Xia QY, et al. Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms(PEComas): a clinicopathological study emphasizing extrarenal PEComas[J]. Histopathology, 2013, 62(4): 642-650. [10] Valencia-Guerrero A, Pinto A, Anderson WJ, et al. PNL2: a useful adjunct biomarker to HMB45 in the diagnosis of uterine perivascular epithelioid cell tumor(PEComa)[J]. Int J Gynecol Pathol, 2020, 39(6): 529-536. [11] Stone JL, Batty T, Nicklin J. Cervical perivascular epithelioid cell tumour(PEComa)of the uterine cervix: cytological findings in a cervical smear[J]. Cytopathology, 2013, 24(4): 272-273. [12] Tajima S, Koda K. Perivascular epithelioid cell tumor of the uterine cervix identified on a conventional cervical smear[J]. Diagn Cytopathol, 2015, 43(12): 1011-1016. [13] Zhang C, Pan F, Qiao J, et al. Perivascular epithelioid cell tumor of the cervix with malignant potential[J]. Int J Gynaecol Obstet, 2013, 123(1): 72-73. [14] Sanfilippo R, Jones RL, Blay JY, et al. Role of chemotherapy, VEGFR inhibitors, and mTOR inhibitors in advanced perivascular epithelioid cell tumors(PEComas)[J]. Clin Cancer Res, 2019, 25(17): 5295-5300. [15] Le P, Garg A, Brandao G, et al. Hormonal manipulation with letrozole in the treatment of metastatic malignant pecoma[J]. Curr Oncol, 2014, 21(3): e518-e520. [16] Chiang S, Vasudevaraja V, Serrano J, et al. TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition[J]. Mod Pathol, 2022, 35(1): 117-127. [17] Wagner AJ, Ravi V, Riedel RF, et al. nab-sirolimus for patients with malignant perivascular epithelioid cell tumors[J]. J Clin Oncol, 2021, 39(33): 3660-3670. [18] Gu X, Yu JJ, Ilter D, et al. Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis[J]. Proc Natl Acad Sci U S A, 2013, 110(37): 14960-14965. [19] Sanfilippo R, Fabbroni C, Fucà G, et al. Addition of antiestrogen treatment in patients with malignant PEComa progressing to mTOR inhibitors[J]. Clin Cancer Res, 2020, 26(20): 5534-5538. [20] McBride A, Garcia AJ, Sanders LJ, et al. Sustained response to pembrolizumab in recurrent perivascular epithelioid cell tumor with elevated expression of programmed death ligand: a case report[J]. J Med Case Rep, 2021, 15(1): 400. [21] 陈筱莉,蹇顺海,杨慧敏,等.伴TFE3基因易位的子宫颈PEComa 1例并文献复习[J].重庆医学, 2020, 49(21): 3569-3573. CHEN Xiaoli, JIAN Shunhai, YANG Huimin, et al. Cervical perivascular epithelioid cell tumor with TFE3 gene translocation: a case report and literature review [J]. Chongqing Medicine, 2020, 49(21): 3569-3573. |
| [1] | 巩性军，吴树明，张供，李守先，庞昕焱. 无顶冠状静脉窦综合征的诊断和外科治疗[J]. 山东大学学报(医学版), 2209, 47(6): 129-. |
| [2] | 吴瑞芳,李长忠. 女性生育力保护的现状与进展[J]. 山东大学学报 (医学版), 2022, 60(9): 1-7. |
| [3] | 韩靖,贾春玲. 肺癌患者胸外手术前治疗牙周基础疾病对预防术后肺炎发生的效果评价[J]. 山东大学学报 (医学版), 2022, 60(9): 113-118. |
| [4] | 王丽慧,高敏,孔北华. 子宫血管肉瘤2例报告并文献复习[J]. 山东大学学报 (医学版), 2022, 60(9): 108-112. |
| [5] | 王文静,刘博策,毕见海,霍然. 超声引导下平阳霉素联合聚桂醇硬化治疗94例囊性淋巴管畸形的疗效[J]. 山东大学学报 (医学版), 2022, 60(8): 72-78. |
| [6] | 彭超,周应芳. 子宫腺肌病的药物治疗进展[J]. 山东大学学报 (医学版), 2022, 60(7): 20-25. |
| [7] | 秦静,杨飞,陈谦,夏涵岱,刘延国,王秀问. 晚期驱动基因阴性、PD-L1表达阴性非鳞非小细胞肺癌一线治疗方案的网状Meta分析[J]. 山东大学学报 (医学版), 2022, 60(7): 74-82. |
| [8] | 王福立,孙银萍,秦杰,荣建胜. DC-CIK细胞联合EGFR-TKI治疗35例老年晚期EGFR突变肺癌的效果[J]. 山东大学学报 (医学版), 2022, 60(7): 110-117. |
| [9] | 王菊,高帅,范玉琛,王凯. 肝衰竭并发真菌感染综合治疗1例[J]. 山东大学学报 (医学版), 2022, 60(5): 125-128. |
| [10] | 孔昕欣,孙书珍,李倩,陈元,周爱华,王莉,姚秀俊. 抗H因子抗体阳性溶血尿毒综合征7例分析[J]. 山东大学学报 (医学版), 2022, 60(4): 82-86. |
| [11] | 李献云,杨甫德. 自杀倾向的认知行为治疗[J]. 山东大学学报 (医学版), 2022, 60(4): 1-9. |
| [12] | 薛美娟,石艳,邵琳琳,王琳,张昀,张阿敏. 遗传性血栓性血小板减少性紫癜1例并文献复习[J]. 山东大学学报 (医学版), 2022, 60(3): 121-124. |
| [13] | 王静,刘粉,曾荣,黄思源,许长娟,梁子婷,董亮. 以胸膜病变为特征的IgG4相关性肺疾病1例[J]. 山东大学学报 (医学版), 2022, 60(3): 114-116. |
| [14] | 潘鹏飞,徐立升,纪坤乾,王得翔,李玉. 以呼吸衰竭起病的线粒体肌病1例及文献回顾[J]. 山东大学学报 (医学版), 2022, 60(2): 54-59. |
| [15] | 宋钰峰,宁豪,姚志刚,吴海虎,刘非凡,吕家驹. 肾上腺海绵状血管瘤临床及影像特征[J]. 山东大学学报 (医学版), 2022, 60(2): 37-42. |
|
